Background {#Sec1}
==========

Gastric cancer is the third leading cause of cancer death worldwide, and almost 1 million new cases occur annually \[[@CR1]\]. With the introduction of mass screening methods such as endoscopy and upper gastrointestinal series, the proportion of patients with early detection of early gastric cancer (EGC) or precancerous adenoma has been increasing \[[@CR2], [@CR3]\]. Endoscopic submucosal dissection (ESD) has become the standard therapy for EGC because it is minimally invasive and allows en bloc and complete resection \[[@CR4]\]. Recently, there has been an attempt to expand the indications of ESD \[[@CR5]\]. Along with this, prediction of lymph node metastasis (LNM) in EGC is becoming more important because LNM is one of the most important factors for assessment of prognosis and decision of therapeutic modalities \[[@CR6], [@CR7]\]. Advanced gastric cancer (AGC) has a particularly poor prognosis compared with EGC. AGC spreads locally by breaking through the gastric wall into neighboring tissue and metastasizes to regional lymph nodes. The presence of metastatic lymph nodes could be an outstanding prognostic factor. Differences in the prognoses of patients with negative lymph node metastasis versus positive lymph node metastasis are especially robust in surgically treated AGC \[[@CR8]--[@CR10]\].

Epithelial-mesenchymal transition (EMT) is a biologic process by which epithelial cells lose their cell-cell junctions and apical-basal polarity and gain a highly motile and invasive phenotype to become mesenchymal cells \[[@CR11]\]. EMT is integral to embryo formation and organ development \[[@CR12]\] and has also been shown to occur during wound healing and tissue fibrosis \[[@CR13]\]. In cancer, EMT contributes pathologically to cancer progression by enabling primary tumor cells to break through the basal lamina and invade adjacent tissue, leading to tumor metastasis \[[@CR14]\].

*Slug*, also known as Snail2, is one of the key transcription factors that activate EMT process in cancer progression \[[@CR15]\]. It contributes to repression of the epithelial phonotype by binding to E-box DNA sequences in the proximal promoter region of the E-cadherin gene \[[@CR16]--[@CR18]\]. This role as a strong E-cadherin repressor mediates loss of tight junctions of epithelial cells and initiates EMT, which facilitates cancer cell invasion and distant metastasis \[[@CR18], [@CR19]\]. *Slug* has been highly studied in various cancers. In breast cancer patients, *Slug* is consistently overexpressed in aggressive and basal-type breast tumors \[[@CR20]\] and seems to be involved in breast tumorigenesis and metastasis through regulation of the EMT \[[@CR21]\]. It has also been demonstrated that *Slug* expression is correlated with poor prognosis in pancreatic and esophageal cancer patients \[[@CR22], [@CR23]\]. Recent studies have revealed that *Slug* not only functions in cancer metastasis, but also plays a role in cancer stemness \[[@CR24], [@CR25]\], implying that *Slug* participates in early steps of cancer progression.

In gastric cancer, upregulation of *Slug* mRNA is associated with suppression of E-cadherin in intestinal and diffuse type gastric carcinomas \[[@CR26]\]. In a study focused on protein expression, high *Slug* expression was correlated with advanced stages and worse clinical outcomes \[[@CR27]\]. However, there are only a few studies on the clinical significance of *Slug* in gastric cancer. In addition, the significance of *Slug* expression in early gastric cancer has not been proved.

Therefore, the purpose of our study was to evaluate the clinical significance of *Slug* expression in gastric cancer using a tissue microarray method in a large series of patients with resected gastric cancer.

Methods {#Sec2}
=======

Patients and clinical samples {#Sec3}
-----------------------------

A total of 459 patients (313 men and 146 women) were randomly selected by random number generation from 2495 consecutive patients with gastric cancer who had undergone radical surgery at Seoul St. Mary's Hospital, The Catholic University of Korea, between 2000 and 2009. Clinicopathological data were reviewed retrospectively from the participants' medical records and pathology reports at our institution. Variable factors including age, gender, type of surgery, tumor size, location, pathologic staging, histology, and lymphatic, venous, and perineural invasion were analyzed. Tumor location was categorized into upper, middle, and lower thirds of the stomach. The gastric cancers were staged according to the pathological tumor/node/metastasis (pTNM) classification (8th edition) of the Union for International Cancer Control \[[@CR28]\]. The histological types of the gastric cancers were assessed according to the 2010 World Health Organization classification \[[@CR29]\]. Tumors were also classified into intestinal, diffuse, and mixed types by Lauren classification \[[@CR30]\]. Written informed consent was obtained from all patients. Patient consent and specimen collection were conducted in accordance with protocols approved by the Institutional Review Board of The Catholic University of Korea (KC14SISI0158).

Tissue microarray construction and immunohistochemistry {#Sec4}
-------------------------------------------------------

All gastric specimens were histologically reviewed, and tissue microarrays (TMAs) were constructed from each of the formalin-fixed, paraffin-embedded (FFPE) tissue blocks using a Manual Tissue Arrayer (Beecher Instruments, Sun Prairie, WI, USA) with a 2.0-mm tip.

Immunohistochemical analysis was performed using primary antibody against Slug (ab188875) (polyclonal; 1:150; Abcam, Cambridge, UK). We determined the optimal dilution of the Slug antibody using positive control tissue such as normal gastric epithelial cells and placenta. Four-micrometer-thick tissue sections from the TMA blocks were transferred to Probe On Plus slides (Fisher Scientific, Pittsburgh, PA, USA) and baked for 2 h in a dry oven at 56 °C (Agilent Technologies, Santa Clara, CA, USA). The FFPE sections were deparaffinized in xylene three times and rehydrated through 100%, 90%, 80%, and 70% ethanol in Tris-buffered saline (pH 7.4). Antigen retrieval was achieved by boiling in 10 mM sodium citrate buffer (pH 6.0) using a microwave oven for 20 min. After treatment with 3% H~2~O~2~ in phosphate-buffered saline, the tissues were incubated with primary antibody at 4 °C overnight and then with diluted (1:100) biotinylated anti-mouse antibody (Abnova, Walnut, CA, USA) for 1 h at room temperature. The signal was amplified using diluted ExtrAvidin-peroxidase (1:50; Sigma-Aldrich, St. Louis, MO, USA) for 1 h at room temperature and visualized using the liquid 3,3′-diaminobenzidine + Substrate Chromogen system (Dako, Glostrup, Denmark). Counterstaining was performed with hematoxylin. Nonspecific staining was not observed in any negative control sections.

Evaluation of immunohistochemical staining {#Sec5}
------------------------------------------

Two pathologists (SH Lee and ES Jung) who were blinded to the clinicopathological parameters independently reviewed the immunohistochemical staining for the tissue sections. We used a semi-quantitative scoring system based on the intensity and extent of stained cells for each case. The staining intensity was graded from 0 to 3 (0 = no expression at all, 1 = weak, 2 = moderate, 3 = strong). The extent was graded from 0 to 3 (0 = \<5%, 1 = 5--25%, 2 = 26--50%, 3 = \>50%). The intensity scores and extent scores were multiplied to obtain the composite score.

Statistical analysis {#Sec6}
--------------------

Continuous data are presented as mean ± standard deviation, and categorical data are presented as quantity and proportion. Pearson's χ^2^ test for categorical variables and Student's t test for unpaired data for continuous variables were performed to compare clinicopathological characteristics among the three *Slug* expression groups. A *P* value \<0.05 was considered significant. Survival rates were calculated by the Kaplan--Meier method, with the date of gastrectomy as the starting point. Patients who were alive were censored at the time of the last follow-up. Differences in survival were examined by the log-rank test. Multivariable analysis was performed using a Cox proportional hazards model with a backward stepwise selection procedure. All analyses were performed by SAS for Windows software (version 8.02, SAS Institute, Cary, NC, USA).

Results {#Sec7}
=======

Expression profile of *Slug* in gastric cancer {#Sec8}
----------------------------------------------

Table [1](#Tab1){ref-type="table"} shows overall immunohistochemical *Slug* expression in the gastric cancer tissue microarray. More than half of the tissues showed diffuse *Slug* expression, which corresponds to extent score 3, and 71.9% (330/459) of tissues showed intensity score 3, indicating strong staining. Figure [1](#Fig1){ref-type="fig"} shows representative images of the range of *Slug* staining intensity. Multiplication of these two variables yielded the *Slug* composite score, which ranged from 0 to 9. Classification of the patients according to *Slug* composite score yielded 104 (22.7%), 130 (28.3%), and 225 (49.0%) patients in the low, mid, and high *Slug* groups, respectively.Table 1Scoring methods of *Slug* expressionMeasuresNumberPercentExtent 0: negative (\<5%)153.3 1: sporadic (5--25%)357.6 2: focal (25--50%)14130.7 3: diffuse (\>50%)26858.4Intensity 0: no staining20.4 1: weak staining245.2 2: moderate staining10322.4 3: strong staining33071.9Extent × Intensity= *Slug* composite score (range 0--9) Low (≤4)10422.7 Mid (6)13028.3 High (9)22549.0 Fig. 1Immunohistochemistry findings showing expression of *Slug* in gastric cancer tissue. **a** no staining. **b** weak staining. **c** moderate staining. **d** strong staining

Relationships between *Slug* expression and clinicopathological parameters {#Sec9}
--------------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} summarizes the clinicopathological characteristics of the 459 patients undergoing gastrectomy for gastric cancer. The mean age of the patients was 58.6 years (range 23--86 years), and 68.2% (*n* = 313) were male. Distal subtotal gastrectomy was the most commonly performed surgery (63.2%). The high *Slug* group tended to have large tumors and advanced tumor depth and stages. They also had a high rate of positive perineural invasion. Regarding histology, the proportion of poorly differentiated adenocarcinoma tended to increase from low to high *Slug* expression groups. However, the proportion of signet ring cell carcinoma was highest in the low *Slug* group.Table 2Comparison of characteristics of the patients according to *Slug* composite scoreMeasuresTotal patients (*N* = 459)Low (*n* = 104)Mid (*n* = 130)High (*n* = 225)*P*Age (years) Mean ± SD58.6 ± 11.956.3 ± 12.358.9 ± 11.859.6 ± 11.60.064 Range23--8623--8132--8224--86Male313 (68.2%)65 (62.5%)94 (72.3%)154 (68.4%)0.276Type of surgery Total gastrectomy166 (36.2%)30 (28.8%)51 (39.2%)85 (37.8%) Subtotal gastrectomy290 (63.2%)73 (70.2%)78 (60.0%)139 (61.8%) Wedge resection3 (0.7%)1 (1.0%)1 (0.8%)1 (0.4%)Tumor size (cm) Mean ± SD5.0 ± 2.94.1 ± 2.55.1 ± 3.35.4 ± 2.80.001 Range0.2--19.00.4--12.50.5--19.00.2--15.5Location Upper third80 (17.4%)16 (15.4%)22 (16.9%)42 (18.7%)0.599 Middle third164 (35.7%)43 (41.3%)50 (38.5%)71 (31.6%) Lower third206 (44.9%)44 (42.3%)55 (42.3%)107 (47.6%) Whole stomach9 (2.0%)1 (1.0%)3 (2.3%)5 (2.2%)Tumor depth (pT) T1120 (26.1%)56 (53.8%)30 (23.1%)34 (15.1%)\<0.001 T262 (13.5%)18 (17.3%)26 (20.0%)18 (8.0%) T3121 (26.4%)14 (13.5%)35 (26.9%)72 (32.0%) T4156 (34.0%)16 (15.4%)39 (30.0%)101 (44.9%)TNM Stage I131 (28.5%)62 (59.6%)37 (28.5%)32 (14.2%)\<0.001 II122 (26.6%)25 (24.0%)45 (34.6%)52 (23.1%) III206 (44.9%)17 (16.3%)48 (36.9%)141 (62.7%)Venous invasion^a^ Negative406 (88.5%)97 (94.2%)117 (90.0%)192 (85.3%)0.055 Positive52 (11.3%)6 (5.8%)13 (10.0%)33 (14.7%)Perineural invasion Negative270 (58.8%)81 (77.9%)75 (57.7%)114 (50.7%)\<0.001 Positive189 (41.2%)23 (22.1%)55 (42.3%)111 (49.3%)Histology Adenocarcinoma0.005^b^  Well differentiated38 (8.3%)12 (11.5%)5 (3.8%)21 (9.3%)  Moderately differentiated136 (29.6%)23 (22.1%)44 (33.8%)69 (30.7%)  Poorly differentiated189 (41.2%)35 (33.7%)53 (40.8%)101 (44.9%) Mucinous adenocarcinoma19 (4.1%)5 (4.8%)7 (5.4%)7 (3.1%) Signet ring cell carcinoma77 (16.8%)29 (27.9%)21 (16.2%)27 (12.0%)Lauren classification Intestinal174 (37.9%)40 (38.5%)47 (36.2%)87 (38.7%)0.433 Diffuse177 (38.6%)40 (38.5%)58 (44.6%)79 (35.1%) Mixed108 (23.5%)24 (23.1%)25 (19.2%)59 (26.2%)Where appropriate, data are shown as the mean ± SD^a^Lymphatic and venous invasion could not be evaluated in 2 and 1 cases, respectively^b^Linear-by-linear association

*Slug* expression and lymph node metastasis {#Sec10}
-------------------------------------------

The rate of positive lymph node metastasis was 36.5% in the low group, 60.8% in the mid group, and 79.1% in the high *Slug* expression group, thus displaying a tendency to increase with increasing *Slug* expression (Table [3](#Tab3){ref-type="table"}). Positive lymph node ratio calculated by dividing number of metastatic LNs by number of retrieved LNs was significantly higher in the high *Slug* group. The high *Slug* group also showed a high proportion of positive lymphatic invasion.Table 3Association of lymphatic metastasis and *Slug* expressionMeasuresTotal patients (*N* = 459)Low (*n* = 104)Mid (*n* = 130)High (*n* = 225)*P*Lymph node metastasis (pN) Negative164 (35.7%)66 (63.5%)51 (39.2%)47 (20.9%)\<0.001 Positive295 (64.3%)38 (36.5%)79 (60.8%)178 (79.1%)  N198 (21.4%)20 (19.2%)30 (23.1%)48 (21.3%)  N299 (21.6%)15 (14.4%)26 (20.0%)58 (25.8%)  N398 (21.4%)3 (2.9%)23 (17.7%)72 (32.0%)   N3a94 (20.5%)3 (2.9%)20 (15.4%)71 (31.6%)   N3b4 (0.9%)0 (0.0%)3 (2.3%)1 (0.4%)Number of metastatic lymph nodes3.7 ± 4.9 (0--42)1.2 ± 2.3 (0--12)3.6 ± 5.8 (0--42)4.9 ± 4.7 (0--25)\<0.001Number of retrieved lymph nodes42.4 ± 15.4 (6--106)39.5 ± 13.3 (14--78)44.9 ± 16.1\* (8--97)42.4 ± 15.8 (6--106)0.028Positive lymph node ratio0.09 ± 0.120.03 ± 0.060.08 ± 0.120.12 ± 0.13\<0.001Lymphatic invasion^a^ Negative154 (33.6%)59 (57.3%)45 (34.9%)50 (22.2%)\<0.001 Positive303 (66.0%)44 (42.7%)84 (65.1%)175 (77.8%)^\*^ *p* \< 0.05; when compared with "low *Slug* composite score group" using the ANOVA test with post-hoc Tukey-HSD test^a^Lymphatic invasion could not be evaluated in 2 cases

In a multivariate logistic regression analysis for lymph node metastasis, *Slug* composite score was identified as an independent predictive factor for lymph node metastasis even after adjusting for age, tumor size, tumor depth, and Lauren classification (Table [4](#Tab4){ref-type="table"}). Compared with patients with low *Slug* score, the adjusted odds ratio in the high *Slug* group was 3.42 (95% confidence interval = 1.74--6.69). Tumor size and depth were also identified as predictive factors for lymph node metastasis.Table 4Multivariate analysis showing independence of the effect on lymph node metastasisNumber of patientsOdds ratio95% CI*P*Age1.010.99--1.040.277Tumor size1.121.00--1.250.049Tumor depth (pT) T1120 (26.1%)1 (ref) T262 (13.5%)17.147.70--38.17\<0.001 T3121 (26.4%)33.9914.87--77.71\<0.001 T4156 (34.0%)13.356.22--28.64\<0.001Lauren classification Intestinal174 (37.9%)1 (ref) Diffuse + Mixed285 (62.1%)1.070.61--1.880.825*Slug* composite score Low104 (22.7%)1 (ref)1.09--1.76 Mid130 (28.3%)1.330.67--2.630.413 High225 (49.0%)3.421.74--6.69\<0.001

The recurrence rates of gastric cancer were compared between the three *Slug* groups (Fig. [2](#Fig2){ref-type="fig"}). Patients with high *Slug* score had the highest tumor recurrence rate. The rate of recurrence was significantly higher in the high *Slug* group than in the low (*P* \< 0.001) and mid (*P* = 0.006) *Slug* groups. There was no statistically significant difference between the low and mid *Slug* groups (*P* = 0.280).Fig. 2Cumulative recurrence rates according to *Slug* expression after gastrectomy

*Slug* expression and survival {#Sec11}
------------------------------

Overall survival rates were determined with respect to the *Slug* composite score using the log rank test (Fig. [3](#Fig3){ref-type="fig"}). The 5-year overall survival rate was significantly worse in the high *Slug* group compared with the mid (61.5% versus 72.4%; *P* = 0.017) and low (61.5% versus 84.6%; P \< 0.001) *Slug* groups. The low *Slug* group had the best 5-year overall survival rate. In multivariable Cox regression analysis including age, gender, TNM stage, Lauren classification, and *Slug* composite score, *Slug* score was not significantly associated with overall survival, whereas age and TNM stage remained independent prognostic factors (Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 3Overall survival according to *Slug* expression after gastrectomy

Subgroup analysis of T1 tumors {#Sec12}
------------------------------

We conducted a subgroup analysis of T1 tumors (Table [5](#Tab5){ref-type="table"}). Negative *Slug* expression was defined as \<5% positive tumor cells or no/weak staining intensity. Tumor depth and size were not significantly different between negative and positive *Slug* expression. Approximately 60% of cases with negative *Slug* expression were signet ring cell carcinoma.Table 5Subgroup analysis of T1 tumor according to *Slug* expressionTotal*Slug* expression*P*Negative (*n* = 13)Positive (*n* = 107)Tumor depth T1a566 (46.2%)50 (46.7%)0.969 T1b647 (53.8%)57 (53.5%)Tumor size3.0 ± 1.92.7 ± 2.03.0 ± 1.90.670Histology Adenocarcinoma, WD250 (0.0%)25 (23.4%)0.001^a^ Adenocarcinoma, MD373 (23.1%)34 (31.8%) Adenocarcinoma, PD312 (15.4%)29 (27.1%) Signet ring cell cancer278 (61.5%)19 (17.8%)Lymph node metastasis Negative10313 (100%)90 (84.1%)0.210^b^ Positive170 (0.0%)17 (15.9%)*WD* well differentiated, *MD* moderately differentiated, *PD* poorly differentiated^a^Linear-by-linear association^b^Fisher's exact test

The rate of lymph node metastasis in T1 tumor was 14.2% (17/120). Patients with negative *Slug* expression showed no lymph node metastasis (0/13), whereas those with positive *Slug* expression showed 15.9% (17/107) lymph node metastasis, with a negative predictive value of 100%.

Discussion {#Sec13}
==========

The present study aimed to determine the relationship between *Slug* expression and prognosis in patients with gastric cancer. High *Slug* expression according to our composite score was observed in about 50% of gastric cancer tissues. We demonstrated that the expression of *Slug* is associated with tumor progression and poor prognosis in gastric cancer. Especially, *Slug* expression was highly correlated with various indicators reflecting lymphatic progression such as lymph node metastasis, lymphatic invasion, and positive lymph node ratio. As it is reasonable to consider that advanced cancer has greater migrating activity and invasiveness than EGC, this finding supports the hypothesis that *Slug*, one of the important EMT drivers, is involved in lymphatic metastasis of gastric cancer through the EMT process. In the case of T1 tumor confirmed after surgical resection, negative *Slug* expression might exclude lymph node metastasis of EGC.

To the best of our knowledge, there is only one previous study that investigated *Slug* protein expression in gastric cancer tissues by immunohistochemical staining \[[@CR27]\]. In that study, 30% of tissues showed positive *Slug* expression, defined as detectable immunoreaction in the perinuclear and other cytoplasmic regions of more than 10% of the cancer cells. This is in contrast to findings from the current study showing that about 75% of gastric cancer patients had mid to high *Slug* expression. A possible explanation for this finding is that many more advanced cancers were included in our study compared to the previous study; approximately 60% of patients in the previous study were stage I, compared with only about 30% in our study. In another previous study based on mRNA expression of *Slug* by real-time quantitative RT-PCR, 58% of gastric cancer patients showed *Slug* upregulation in the tumor, which is in close agreement with our finding \[[@CR26]\]. Moreover, the tendency for *Slug* expression to be associated with advanced pTNM stages was observed in both studies \[[@CR26], [@CR27]\]. The correlation of *Slug* expression with increased tumor size and perineural invasion was newly identified in the present study.

We focused on the association of lymphatic metastasis and *Slug* expression because *Slug* can activate the EMT process. For this purpose, we used the *Slug* composite score to produce a more continuous scale (low, mid, and high *Slug* groups) instead of dichotomizing the patient groups. As expected, higher *Slug* expression was associated with more prevalent lymph node metastasis and lymphatic invasion. In addition, the positive lymph node ratio gradually increased with increasing *Slug* score. This ratio represents lymph node metastasis density \[[@CR31]\]. Much study has focused on this ratio because it has global prognostic relevance in gastric cancer regardless of stage in multivariable analysis and is more sophisticated than conventional nodal metastasis in TNM staging for predicting prognosis \[[@CR32]\]. In addition, we demonstrated that *Slug* expression is an independent prognostic factor for lymph node metastasis in gastric cancer patients even after adjustment for well-known prognostic factors including tumor size and depth of tumor invasion.

The current study indicates that *Slug* expression correlates well with overall survival as well as tumor recurrence. The high *Slug* expression group had the worst long-term survival rate and the highest tumor recurrence rate. These results correspond well with previous studies, in which positive *Slug* expression was associated with distant metastasis and poor postoperative 5-year survival \[[@CR26], [@CR27]\]. To our knowledge, this is the first report of long-term survival and recurrence data according to *Slug* expression and suggests that EMT signaling with involvement of *Slug* could affect long-term prognosis after gastrectomy of gastric cancer patients.

In a subgroup analysis of T1 tumors, we documented that *Slug* expression is associated with unexpected lymph node metastasis in EGC. EGC is defined as gastric cancer that invades no more deeply than the submucosa, irrespective of lymph node metastasis \[[@CR33]\]. It has been reported that about 10--15% of patients with EGC have lymph node metastasis \[[@CR1], [@CR34], [@CR35]\]. Precise prediction of lymph node metastasis status in EGC is a very important issue because ESD has become increasingly popular as a minimally invasive treatment for EGC \[[@CR36]\]. We applied strict criteria for negative *Slug* expression in order to increase the negative predictive value because false negative results could be fatal when making the decision between surgical resection and ESD. In our study, all patients with T1 tumor and negative *Slug* expression showed no lymph node metastasis even though some of them had submucosal tumor invasion (T1b) or undifferentiated (poorly differentiated or signet ring cell) type histology. Tumor depth beyond submucosa and histological differentiation are well known independent risk factors for lymph node metastasis of EGC \[[@CR37], [@CR38]\]. Interestingly, 8 of 13 Slug negative T1 tumors were signet ring cell cancer. A previous study showed that signet ring foci of 8 patients with hereditary diffuse gastric cancer had a low proliferative index and there was no evidence for EMT \[[@CR39]\]. This finding corresponds well with our result.

Our study has some strengths. First, a relatively large number of patients were randomly selected from consecutive patients undergoing surgery for gastric cancer for TMA and analyzed. Moreover, we present a novel finding regarding greater than 5-year survival and tumor recurrence according to *Slug* expression. In addition, this is the first report to document the significance of Slug expression in EGC.

Conclusions {#Sec14}
===========

Our data demonstrated that high expression of *Slug* in gastric cancer tissue was associated with higher tumor recurrence rate and poor long-term survival. In particular, in cases with lymph node metastasis *Slug* expression was an independent predictive factor regardless of tumor size or depth of tumor invasion. Negative *Slug* expression showed high negative predictive value for lymph node metastasis in EGC, which could have potential for future use in discriminating patients with EGC at high risk of lymph node metastasis.
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===============
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AGC

:   Advanced gastric cancer

EGC

:   Early gastric cancer

EMT

:   Epithelial--mesenchymal transition

ESD

:   Endoscopic submucosal dissection

FFPE

:   Formalin-fixed, paraffin-embedded

LNM

:   Lymph node metastasis

pTNM

:   Pathological tumor/node/metastasis

TMAs

:   Tissue microarrays

**Electronic supplementary material**

The online version of this article (10.1186/s12885-017-3668-8) contains supplementary material, which is available to authorized users.

Not applicable

Funding {#FPar1}
=======

This study was supported by Research Fund of College of Medicine, The Catholic University of Korea, by a program of Catholic Medical Center Research Foundation made in 2014, and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (NRF-2016R1C1B2015185).

Availability of data and materials {#FPar2}
==================================

Attributing to the privacy of patients, the patient information is publicly inaccessible.

HHL participated in the study design, performed the data collection and chart review, and drafted the manuscript with help of other authors. SHL participated in planning the study, performed histological examination of the samples, evaluated IHC results and helped finalize the manuscript. KYS designed the treatment protocol, performed the surgeries, and helped finalize the manuscript. SJN and JHO participated in the study design. JMP participated in the study design and helped finalize the manuscript. ESJ performed the pathological studies and made pathology pictures. MGC participated in planning the study and helped to gather clinical data. CHP participated in planning the study and performed the surgeries. All authors have read and approved the final version of this manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The study with human samples was approved by the Ethics Committee of the Catholic University of Korea (KC14SISI0158). We clarify that all clinical samples described here were gained from patients who had given written informed consent.

Consent for publication {#FPar4}
=======================

Not applicable

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
